David Keire received a Ph.D. in Analytical Chemistry at the University of California, Riverside in 1990 with a focus on NMR spectroscopy. He subsequently performed postdoctoral research at Purdue University before joining the Division of Immunology of the Beckman Research Institute of the City of Hope National Medical Center in 1992. In 1999 he was recruited by the Digestive Diseases Division of the UCLA School of Medicine as a Researcher for studies on the role of gut peptide hormones on satiety and hunger. In 2008 he joined the FDA and currently is Director of the CDER/OPQ Office of Testing and Research Division of Pharmaceutical Analysis based in St Louis. David’s analytical chemistry skills have been put to use at the FDA on studies of complex drugs (e.g., heparin, protamine sulfate, glatiramer acetate, transdermal systems, inhalers, modified release dosage forms and protein-based therapeutics). In 2018 he was appointed to a Senior Biomedical Research Scientist role at the FDA. Currently, he maintains a research program in the identification and evaluation of state-of-the-art analytical technologies for drug analysis to provide scientific input on drug quality questions to FDA assessors. He has over 90 peer reviewed research articles and 8 book chapters describing his work.